OSE-2101

Published

dm+d

Unassigned

New Medicines

TedopiNon-small cell lung cancer (NSCLC), HLA-A2 positive, stage IIIB or IV - second-line or greater

Information

Tedopi
Vaccine
OSE Pharma
OSE Pharma

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

A vaccine targeting five tumour-associated antigens found in various tumours.
Lung cancer is the second most common cancer in the UK, with 44,488 new cases in the UK in 2012; about 87% are classified as NSCLC [2]. About 45% of these express the HLA-A2 markers [3].
Non-small cell lung cancer (NSCLC), HLA-A2 positive, stage IIIB or IV - second-line or greater
Subcutaneous injection